Engagement with Diabetes Retinal Screening: An analysis of secondary data from the Pacific Eye Institute in Suva Diabetes retinal screening

Main Article Content

Joshua Cronin-Lampe
Alana Cavadino
Harris Ansari
Faufiva Fa'alau
Judith Mccool

Keywords

Diabetes mellitus, Diabetic Retinopathy, Screening, Engagement

Abstract

Abstract


Objectives: Diabetic retinopathy (DR) is one of the primary causes of preventable vision loss and blindness. Diabetic retinopathy screening (DRS) is essential to detect microvascular damage to the retina; it can be performed in primary care or specialist eye health clinics. The system of referral, screening, and treatment relies on an organized primary care referral pathway, accessible services, and at least a basic level of health literacy among those living with or under threat of developing Diabetes Mellitus (DM).


 


Methods: Routinely collected patient data from the Pacific Eye Institute (PEI) in Fiji was analyzed to describe a) clinical and demographic DR patient characteristics and b) characteristics of patients demonstrating higher clinic engagement (using multiple logistic regression).


 


Results: Of 9287 patients who first attended the PEI for DRS between 2012 and 2017, 22% presented with sight-threatening diabetic retinopathy (STDR) in at least one eye. The average duration of DM was 3 years; self-reported glycaemic control was poor. Indo-Fijian or other ethnicity (both vs iTaukei, OR=2.30, 95%CI 1.96-2.70 and OR=2.18, 95% CI 1.63-2.92, respectively; p<0.001), high blood sugar (OR 1.39, 95%CI 1.10-1.75, p=0.006), longer duration of disease (OR=1.21, 95%CI 1.02-1.43, p=0.027), peripheral neuropathy (OR=1.43, 95%CI 1.24-1.65, p<0.001) and STDR (OR=3.30, 95%CI 2.78-3.92, p<0.001) were associated with greater odds of higher clinic engagement. Male gender (Odds Ratio (OR)=0.83, 95% Confidence Interval (CI) 0.72-0.95, p=0.006), younger or older age (both vs 40-70 years; <40 years, OR=0.48, 95%CI 0.37-0.63, ?70 years OR=0.61, 95%CI 0.48-0.76, p<0.001), year of first clinic visit (2013 vs 2012 OR=0.58, 95%CI 0.50-0.69, p<0.001; 2014 vs 2012 OR=0.36, 95%CI 0.30-0.43, p<0.001) and moderate visual impairment (OR=0.67 95%CI 0.56-0.80, p<0.001) were associated with lower odds of high clinic engagement.


 


Conclusion: Our results identify patient groups that may be more vulnerable to lower engagement with eye health services. Increasing engagement may help reduce delays in screening and treatment. Given the projected continued rise in DM in the Pacific region, investing in robust electronic data systems that collect and connect public health and clinical data is imperative. Health literacy is important for the prevention of DM, timely DM diagnosis, and screening for complications such as DR.

Abstract 132 | PDF Downloads 4

References

1. Leasher JL, Bourne RR, Flaxman SR, et al. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care 2016;39(9):1643-9. doi: https://dx.doi.org/10.2337/dc15-2171
2. Cheloni R, Gandolfi SA, Signorelli C, et al. Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. BMJ Open 2019;9(3):e022188. doi: https://dx.doi.org/10.1136/bmjopen-2018-022188
3. Lee R, Wong TY, C. S. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and vision 2015;2(17) doi: doi: 10.1186/s40662-015-0026-
4. Wong TY, Sun J, Kawasaki R, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology 2018;125(10):1608-22. doi: https://dx.doi.org/10.1016/j.ophtha.2018.04.007
5. Chua J, Lim CXY, Wong TY, et al. Diabetic Retinopathy in the Asia-Pacific. 2018;7(1):3-16. doi: 10.22608/apo.2017511
6. Kool B, Webber M, J. M. DR services in Fiji: Attitudes, barriers and screening practices. Community Eye Health 2015;28(92)
7. Szetu J, Sikivou B, Nilesse M, et al. Growing leadership in eye health in the Pacific Islands region. In: Withers M MJ, ed. Global health leadership: Case studies from the Asia-Pacific: Springer International Publishing 2019.
8. Tuiketei T, A. R. Report on the assessment of diabetic retinopathy and diabetes management systems in Fiji. Suva, Fiji: The Pacific Eye Institute, 2015.
9. Damato EM, Murray N, Szetu J, et al. Sight-threatening diabetic retinopathy at presentation to screening services in Fiji. Ophthalmic Epidemiology 2014;21(5):318-26. doi: doi: 10.3109/09286586.2014.949781.
10. Brian G, Sikivou B, Fischer-Harder K, et al. Diabetic eye disease among adults in Fiji with previously undiagnosed diabetes. Clin Experiment Ophthalmol 2011;39(7):682-90. doi: doi: 10.1111/j.1442-9071.2011.02533.x.
11. Ministry of Health. Diabetic Retinal Screening, Grading, Monitoring and Referral Guidance. . Wellington, New Zealand: Ministry of Health, 2016.
12. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. The Lancet Global Health 2017;5(12):e1221-e34. doi: https://dx.doi.org/10.1016/S2214-109X(17)30393-5
13. Burton MJ, Faal HB, Ramke J ea. Announcing the lancet global health commission on global eye health. The Lancet Global Health 2019;7(12):e1612-e13. doi: doi: 10.1016/S2214-109X(19)30450-4.
14. Kashim RM, Newton P, O O. Diabetic retinopathy screening: A systematic review on patients' non-attendance. IntJEnvironResPublic Health 2018;15(1) doi: doi: 10.3390/ijerph15010157.
15. Das A. Diabetic Retinopathy: Battling the Global Epidemic. Invest Ophthalmol Vis Sci 2016;57(15):6669-82. doi: https://dx.doi.org/10.1167/iovs.16-21031